San Antonio Breast Cancer Symposium | Conference

Dr. Hurvitz on Using ADCs in HER2+ Breast Cancer

December 12th 2019

Sara A. Hurvitz, MD, associate professor of medicine and medical oncologist, University of California Los Angeles, discusses the use of antibody-drug conjugates in HER2-positive breast cancer.

Adjuvant T-DM1 for Early HER2+ Breast Cancer Demonstrates Low Recurrence Rate

December 12th 2019

The first reported data for adjuvant ado-trastuzumab emtansine in early HER2-positive breast cancer showed high rates of disease control in a randomized trial designed to compare toxicities with trastuzumab and paclitaxel.

Margetuximab Update Elucidates Clinical Benefit in HER2+ Metastatic Breast Cancer

December 12th 2019

Margetuximab continued to show a clear progression-free survival benefit and a trend toward an overall survival benefit versus trastuzumab (Herceptin) when either agent was combined with chemotherapy in patients with HER2-positive metastatic breast cancer who had received prior anti-HER2 therapies.

Adjuvant Pertuzumab Regimen Shows Modest OS Benefit in HER2+ Early Breast Cancer

December 12th 2019

Adjuvant pertuzumab (Perjeta) with trastuzumab (Herceptin) plus chemotherapy showed a 0.9% improvement in overall survival and continued to reduce the risk of disease recurrence in patients with HER2-positive early breast cancer.

Tucatinib Boosts Survival in HER2+ Breast Cancer, FDA Submission Imminent

December 12th 2019

Adding tucatinib to trastuzumab (Herceptin) and capecitabine (Xeloda) reduced the risk of death by 34% in heavily pretreated patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

S-1 Improves iDFS in HR+, HER2- Breast Cancer

December 12th 2019

Adding the novel oral fluoropyrimidine derivative S-1 to adjuvant endocrine therapy significantly improved invasive disease-free survival for Japanese patients with HR-positive, HER2-negative breast cancer.

T-DXd Shows Potential to Establish New Standard of Care in Advanced HER2+ Breast Cancer

December 11th 2019

Trastuzumab deruxtecan (T-DXd; DS-8201) induced a confirmed objective response rate of almost 61% and a durable benefit in heavily pretreated patients with advanced HER2-positive breast cancer.

TAILORx Update Shows Different PRO Profiles for Chemo, Endocrine Therapy for Breast Cancer

December 10th 2018

Chemotherapy for breast cancer caused significantly more acute symptoms as compared with endocrine therapy, although the adverse effects of endocrine therapy increased over time.

CAR T-Cell Therapy Shows Early Potential in TNBC

December 8th 2018

Chimeric antigen receptor T cells targeting the tyrosine kinase receptor ROR1 can be transferred into patients safely and the cells expand in vivo.

Telephone-Based Lifestyle Interventions Improved Breast Cancer Outcomes

December 8th 2018

Early-stage breast cancer survivors who completed a telephone-based lifestyle intervention program lost weight and tended to have higher rates of disease-free survival.

Durvalumab/Olaparib Combo Is Active in BRCA-Mutated Metastatic Breast Cancer

December 8th 2018

The combination of olaparib and durvalumab in patients with HER2-negative metastatic breast cancer with germline BRCA mutations is well tolerated and has promising activity, especially in earlier settings.

Breast Cancer Surgery Choice May Affect Quality of Life in Younger Patients

December 8th 2018

Younger patients with breast cancer who underwent lumpectomy had better quality of life than women who had a mastectomy.

Exercise Helps Women Maintain Cardiovascular Function During Adjuvant Breast Cancer Treatment

December 7th 2018

Women who took part in a supervised exercise program during adjuvant treatment for breast cancer had better cardiovascular function than women who did not participate in the program.

Palbociclib Combo Active in HER2+ Breast Cancer

December 7th 2018

The combination of palbociclib and trastuzumab demonstrated safety and efficacy in patients with advanced estrogen receptor–positive/HER2-positive breast cancer.

Oxybutynin Decreases Hot Flashes, Improves Quality of Life in Breast Cancer Survivors

December 7th 2018

Oxybutynin helped to reduce the frequency and intensity of hot flashes among women who could not take hormone replacement therapy in survivorship.

Venetoclax Has Impressive Activity in ER+ and BCL-2+ Breast Cancer

December 7th 2018

Combining the BCL-2 inhibitor venetoclax with endocrine therapy elicited notable activity with a tolerable safety profile in patients with estrogen receptor–positive and BCL-2–positive metastatic breast cancer.

Dr. Spring on the Association Between pCR and Neoadjuvant Chemotherapy

December 7th 2018

Laura Spring, MD, medical oncologist at Massachusetts General Hospital Cancer Center and instructor in medicine at Harvard Medical School, discusses the association between pathologic complete response (pCR) and neoadjuvant chemotherapy in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

Dr. Leon Ferre on the Results of the Randomized Trial of Oxybutynin for Hot Flashes

December 7th 2018

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses the randomized trial evaluating the effectiveness of oxybutynin chloride in the management of hot flashes in patients with breast cancer at the 2018 San Antonio Breast Cancer Symposium.

Extended PFS Observed in Alpelisib Combo for PIK3CA-Mutant Breast Cancer

December 7th 2018

Additional analyses from the SOLAR-1 study show that alpelisib, an investigational alpha-specific PI3K inhibitor, combined with fulvestrant extended progression-free survival compared with fulvestrant alone in patients with PIK3CA-mutant advanced breast cancer regardless of line of therapy or prior CDK4/6 inhibitor treatment.

HER3-Targeting Antibody-Drug Conjugate Shows Encouraging Activity in Advanced Breast Cancer

December 7th 2018

U3-1402, an investigational antibody-drug conjugate targeting HER3, induced objective response in more than 40% of heavily pretreated patients with HER3-expressing breast cancer.

x